ニューロモジュレーション市場規模、シェア、動向、2030年までの世界予測

ニューロモジュレーション市場 – 技術（内部、外部）、刺激の種類（脊髄、脳深部、迷走神経刺激）、用途（虚血、うつ病、てんかん、肥満）、エンドユーザー（病院、ASC、クリニック）および地域別 – 2030年までの世界予測

本レポートは、ニューロモジュレーション市場を、技術、刺激の種類、用途、エンドユーザー、および国別に分析しています。また、市場の成長に影響を与える推進要因、制約要因、機会、課題といった要因に加え、市場リーダーの競争環境についても詳細に分析しています。さらに、ミクロ市場をそれぞれの成長トレンドに沿って分析し、5つの主要地域とそれぞれの国における市場セグメントの収益予測も示しています。
本レポートは、既存企業と中小規模企業の両方にとって、市場動向の理解を深め、ひいては市場シェアの拡大に貢献します。本レポートをご購入いただいた企業は、以下に挙げる戦略のいずれか、または組み合わせて活用することで、市場における地位を強化できます。

世界のニューロモジュレーション市場は、予測期間中に9.4%のCAGRで成長し、2025年の68億1,000万米ドルから2030年には106億8,000万米ドルに達すると予測されています。

ニューロモジュレーション市場は、神経疾患の有病率の上昇、新たなニューロモジュレーション技術の開発、そして高齢化人口の増加により拡大しており、これらはすべて市場の成長に寄与しています。しかし、ニューロモジュレーション治療の高額な費用が市場の成長を阻害する可能性もあります。

The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.

The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.

“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”

By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.

“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”

The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson’s disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.

“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”

The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30%
• By Designation: C Level: 30%, Director Level: 34%, and Others: 36%
• By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).

Research Coverage

This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.

Reasons to Buy the Report

The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.

This report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

Table of Contents

1               INTRODUCTION              37

1.1           STUDY OBJECTIVES       37

1.2           MARKET DEFINITION   37

1.3           STUDY SCOPE   38

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 38

1.3.2        INCLUSIONS & EXCLUSIONS       39

1.3.3        YEARS CONSIDERED      40

1.3.4        CURRENCY CONSIDERED            41

1.4           STAKEHOLDERS               41

1.5           SUMMARY OF CHANGES               41

2               RESEARCH METHODOLOGY       43

2.1           RESEARCH DATA              43

2.1.1        SECONDARY DATA          44

2.1.1.1    List of key secondary sources              44

2.1.1.2    Key data from secondary sources       44

2.1.2        PRIMARY DATA 45

2.1.2.1    Key objectives of primary research    45

2.1.2.2    List of primary sources        45

2.1.2.3    Key data from primary sources           46

2.1.2.4    Breakdown of primary interviews      47

2.1.2.5    Insights from industry experts            48

2.2           MARKET SIZE ESTIMATION         48

2.2.1        BOTTOM-UP APPROACH              48

2.2.1.1    Revenue estimation of key players     49

2.2.1.2    Study of annual reports and investor presentations        49

2.2.1.3    Primary interviews                49

2.2.1.4    Growth forecast    49

2.2.1.5    CAGR projections                 50

2.2.2        TOP-DOWN APPROACH                50

2.3           DATA TRIANGULATION                51

2.4           STUDY ASSUMPTIONS  52

2.4.1        RESEARCH-RELATED ASSUMPTIONS      52

2.4.2        PARAMETRIC ASSUMPTIONS     52

2.4.3        GROWTH-RATE ASSUMPTIONS 52

2.4.4        MARKET ASSUMPTIONS               53

2.5           RESEARCH LIMITATIONS             53

2.6           RISK ANALYSIS  54

3               EXECUTIVE SUMMARY  55

4               PREMIUM INSIGHTS       59

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET                 59

4.2           ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024           60

4.3           NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES         61

4.4           NEUROMODULATION MARKET: REGIONAL MIX                 62

5               MARKET OVERVIEW       63

5.1           INTRODUCTION              63

5.2           MARKET DYNAMICS       63

5.2.1        DRIVERS               64

5.2.1.1    Rising prevalence of neurological disorders and nerve injuries                 64

5.2.1.2    High incidence of neurological disorders among geriatric population              64

5.2.1.3    Favorable government support and funding with advanced healthcare infrastructure     65

5.2.1.4    Development of advanced neuromodulation and neurostimulation technologies            65

5.2.1.5    Growing collaborations among device manufacturers, healthcare providers, and research institutions  66

5.2.1.6    Availability of reimbursements for neuromodulation devices                 66

5.2.2        RESTRAINTS      66

5.2.2.1    High cost of neuromodulation procedures       66

5.2.2.2    Preference for drug therapies over neuromodulation products                 67

5.2.2.3    Adverse effects and complications with neuromodulation devices                 67

5.2.3        OPPORTUNITIES              67

5.2.3.1    Large population and high healthcare expenditure in emerging economies              67

5.2.3.2    Widening application scope of neuromodulation            68

5.2.4        CHALLENGES    68

5.2.4.1    Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices      68

5.2.4.2    Shortage of trained professionals       69

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            69

5.4           PRICING ANALYSIS          70

5.4.1        AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS,

BY STIMULATION TYPE, 2023–2025           70

5.4.2        AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS,

BY KEY PLAYER, 2023–2025            70

5.4.3        AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS,

BY REGION, 2023–2025    71

5.5           VALUE CHAIN ANALYSIS               72

5.6           SUPPLY CHAIN ANALYSIS             73

5.7           ECOSYSTEM ANALYSIS  74

5.8           INVESTMENT & FUNDING SCENARIO     75

5.9           TECHNOLOGY ANALYSIS             76

5.9.1        KEY TECHNOLOGIES     76

5.9.1.1    Transcutaneous electrical nerve stimulation    76

5.9.2        COMPLEMENTARY TECHNOLOGIES       77

5.9.2.1    Wearable biosensors             77

5.9.3        ADJACENT TECHNOLOGIES       77

5.9.3.1    Regenerative medicine and stem cells               77

5.10         PATENT ANALYSIS          77

5.10.1      LIST OF KEY PATENTS   79

5.11         TRADE DATA ANALYSIS                80

5.11.1      IMPORT DATA FOR HS CODE 901890       80

5.11.2      EXPORT DATA FOR HS CODE 901890       80

5.12         KEY CONFERENCES & EVENTS, 2025–2026              81

5.13         CASE STUDY ANALYSIS 82

5.13.1      USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH,

CLINICAL PRACTICE, AND CONSUMER APPLICATIONS 82

5.13.2      PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS              82

5.13.3      APPLICATION OF NEUROMODULATION TECHNIQUES—FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION        83

5.14         REGULATORY ANALYSIS               84

5.14.1      REGULATORY LANDSCAPE         84

5.14.1.1  North America      84

5.14.1.1.1                US           84

5.14.1.1.2                Canada   84

5.14.1.2  Europe   84

5.14.1.3  Asia Pacific            85

5.14.1.3.1                China      85

5.14.1.3.2                Japan      85

5.14.1.3.3                India       86

5.14.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             87

5.15         PORTER’S FIVE FORCES ANALYSIS           89

5.15.1      BARGAINING POWER OF SUPPLIERS       90

5.15.2      BARGAINING POWER OF BUYERS             90

5.15.3      THREAT OF NEW ENTRANTS      90

5.15.4      THREAT OF SUBSTITUTES          90

5.15.5      INTENSITY OF COMPETITIVE RIVALRY 91

5.16         KEY STAKEHOLDERS & BUYING CRITERIA            91

5.16.1      KEY STAKEHOLDERS IN BUYING PROCESS           91

5.16.2      KEY BUYING CRITERIA  92

5.17         IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET               92

5.17.1      INTRODUCTION              92

5.17.2      POTENTIAL OF AI            93

5.17.3      IMPACT OF AI   93

5.17.4      KEY COMPANIES IMPLEMENTING AI      94

5.17.5      FUTURE OF AI   94

5.18         IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET               94

5.18.1      INTRODUCTION              94

5.18.2      KEY TARIFF RATES          95

5.18.3      PRICE IMPACT ANALYSIS             96

5.18.4      IMPACT ON COUNTRY/REGION                96

5.18.4.1  North America      96

5.18.4.2  Europe   96

5.18.4.3  Asia Pacific            97

5.18.5      IMPACT ON END-USE INDUSTRIES          97

5.18.5.1  Hospitals                97

6               NEUROMODULATION MARKET, BY TECHNOLOGY                 98

6.1           INTRODUCTION              99

6.2           INTERNAL NEUROMODULATION             99

6.2.1        INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT

RESULTS AND LOWER HEALTHCARE COSTS       99

6.3           EXTERNAL NEUROMODULATION            101

6.3.1        RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL

AND PAIN-RELATED DISORDERS TO FUEL GROWTH      101

7               NEUROMODULATION MARKET, BY STIMULATION TYPE     105

7.1           INTRODUCTION              106

7.2           SPINAL CORD STIMULATION     107

7.2.1        GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH               107

7.3           DEEP BRAIN STIMULATION        110

7.3.1        MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS   110

7.4           SACRAL NERVE STIMULATION  113

7.4.1        INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH          113

7.5           VAGUS NERVE STIMULATION    116

7.5.1        RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY                 116

7.6           GASTRIC NERVE STIMULATION                119

7.6.1        INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH             119

7.7           TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION                 122

7.7.1        LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR  122

7.8           TRANSCRANIAL MAGNETIC STIMULATION         125

7.8.1        MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND             125

7.9           RESPIRATORY ELECTRICAL STIMULATION         128

7.9.1        HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH          128

7.10         OTHER STIMULATION TYPES    131

8               NEUROMODULATION MARKET, BY APPLICATION                 135

8.1           INTRODUCTION              136

8.2           NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION             136

8.2.1        CHRONIC PAIN 136

8.2.1.1    High incidence of chronic pain among geriatric population to support market growth        136

8.2.2        FAILED BACK SURGERY SYNDROME       139

8.2.2.1    Increasing number of spinal surgeries to aid market growth                 139

8.2.3        ISCHEMIA            142

8.2.3.1    High effectiveness of neuromodulation to boost effectiveness for ischemia treatment               142

8.3           NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION             144

8.3.1        PARKINSON’S DISEASE 144

8.3.1.1    Development of advanced solutions and increased R&D to improve market growth       144

8.3.2        TREMORS            147

8.3.2.1    Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market 147

8.3.3        DEPRESSION     149

8.3.3.1    Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment      149

8.3.4        OTHER DEEP BRAIN STIMULATION APPLICATIONS                 152

8.4           NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION             155

8.4.1        URINE INCONTINENCE 155

8.4.1.1    High incidence of urine incontinence to offer growth opportunities for market players        155

8.4.2        FECAL INCONTINENCE 158

8.4.2.1    Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence  158

8.5           NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION             161

8.5.1        EPILEPSY             161

8.5.1.1    Low risk with device implantation and long-lasting battery life to aid market growth                 161

8.5.2        OTHER VAGUS NERVE STIMULATION APPLICATIONS                 163

8.6           NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION             166

8.6.1        GASTROPARESIS              166

8.6.1.1    Reduced hospitalization time associated with sastroparesis treatment to augment market growth                166

8.6.2        OBESITY              169

8.6.2.1    High prevalence of obesity and risks associated with gastric bypass to propel market growth         169

8.7           NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION   172

8.7.1        TREATMENT-RESISTANT DEPRESSION 172

8.7.1.1    High prevalence of chronic and recurrent depression to augment market growth       172

8.7.2        OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS  175

8.8           NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,

BY APPLICATION             178

8.8.1        DEPRESSION     179

8.8.1.1    Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients    179

8.8.2        MIGRAINE           181

8.8.2.1    High prevalence of migraines to support market growth                 181

8.9           NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION,

BY APPLICATION             184

8.9.1        INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS             184

8.10         OTHER APPLICATIONS 186

9               NEUROMODULATION MARKET, BY END USER   189

9.1           INTRODUCTION              190

9.2           HOSPITALS & AMBULATORY SURGERY CENTERS                 190

9.2.1        ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH          190

9.3           CLINICS & PHYSIOTHERAPY CENTERS   193

9.3.1        NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION        193

9.4           OTHER END USERS         196

10            NEUROMODULATION MARKET, BY REGION       199

10.1         INTRODUCTION              200

10.2         NORTH AMERICA             200

10.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 200

10.2.2      US           206

10.2.2.1  US to dominate North American neuromodulation market during forecast period      206

10.2.3      CANADA               210

10.2.3.1  Increasing neurological disorder rates and rising government funding to propel market growth       210

10.3         EUROPE               214

10.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      215

10.3.2      GERMANY           220

10.3.2.1  Advanced surgical innovations and favorable reimbursement policies to drive market       220

10.3.3      FRANCE                224

10.3.3.1  Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques              224

10.3.4      UK          228

10.3.4.1  Increased public & private sector healthcare expenditure and investments to fuel market growth    228

10.3.5      ITALY    232

10.3.5.1  Rising cases of dementia and Alzheimer’s among geriatric population to spur market growth     232

10.3.6      SPAIN    236

10.3.6.1  Favorable government-led healthcare initiatives to support market growth       236

10.3.7      RUSSIA 240

10.3.7.1  Shifting demographic landscape and escalating neurological health needs to drive demand             240

10.3.8      REST OF EUROPE             244

10.4         ASIA PACIFIC     248

10.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 248

10.4.2      CHINA  254

10.4.2.1  Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand               254

10.4.3      JAPAN   258

10.4.3.1  Innovative healthcare delivery and advanced infrastructure landscape to augment market growth                258

10.4.4      INDIA    262

10.4.4.1  Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth             262

10.4.5      AUSTRALIA         266

10.4.5.1  Increasing cases of depressive and post-traumatic stress disorders to propel market demand    266

10.4.6      REST OF ASIA PACIFIC   270

10.5         LATIN AMERICA                274

10.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 275

10.5.2      BRAZIL 279

10.5.2.1  Improvements in healthcare infrastructure to aid market growth                 279

10.5.3      MEXICO                283

10.5.3.1  Expanding healthcare awareness and growing burden of neurological disorders to favor market growth 283

10.5.4      REST OF LATIN AMERICA             287

10.6         MIDDLE EAST & AFRICA                291

10.6.1      IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET 291

10.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 292

11            COMPETITIVE LANDSCAPE         297

11.1         INTRODUCTION              297

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            297

11.2.1      MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET                 297

11.3         REVENUE ANALYSIS, 2020–2024  298

11.4         MARKET SHARE ANALYSIS, 2024                 299

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 301

11.5.1      STARS   301

11.5.2      EMERGING LEADERS     301

11.5.3      PERVASIVE PLAYERS      302

11.5.4      PARTICIPANTS 302

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         303

11.5.5.1  Company footprint               303

11.5.5.2  Region footprint   303

11.5.5.3  Technology footprint           304

11.5.5.4  Stimulation type footprint   304

11.5.5.5  End-user footprint                305

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        305

11.6.1      PROGRESSIVE COMPANIES         305

11.6.2      RESPONSIVE COMPANIES            305

11.6.3      DYNAMIC COMPANIES  305

11.6.4      STARTING BLOCKS         306

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 307

11.6.5.1  Detailed list of key startups/SMEs    307

11.6.5.2  Competitive benchmarking of startups/SMEs 308

11.7         COMPANY VALUATION & FINANCIAL METRICS 310

11.7.1      COMPANY VALUATION 310

11.7.2      FINANCIAL METRICS      310

11.8         BRAND/PRODUCT COMPARISON             311

11.9         COMPETITIVE SCENARIO             312

11.9.1      PRODUCT LAUNCHES & APPROVALS     312

11.9.2      DEALS  313

12            COMPANY PROFILES      314

12.1         KEY PLAYERS     314

12.1.1      MEDTRONIC      314

12.1.1.1  Business overview 314

12.1.1.2  Products offered   316

12.1.1.3  Recent developments           316

12.1.1.3.1                Product approvals 316

12.1.1.4  MnM view              317

12.1.1.4.1                Right to win           317

12.1.1.4.2                Strategic choices   317

12.1.1.4.3                Weaknesses & competitive threats     317

12.1.2      BOSTON SCIENTIFIC CORPORATION     318

12.1.2.1  Business overview 318

12.1.2.2  Products offered   320

12.1.2.3  Recent developments           320

12.1.2.3.1                Product approvals 320

12.1.2.3.2                Deals      321

12.1.2.4  MnM view              321

12.1.2.4.1                Right to win           321

12.1.2.4.2                Strategic choices   321

12.1.2.4.3                Weaknesses & competitive threats     321

12.1.3      ABBOTT               322

12.1.3.1  Business overview 322

12.1.3.2  Products offered   323

12.1.3.3  Recent developments           324

12.1.3.3.1                Product launches and approvals         324

12.1.3.4  MnM view              324

12.1.3.4.1                Right to win           324

12.1.3.4.2                Strategic choices   324

12.1.3.4.3                Weaknesses & competitive threats     324

12.1.4      LIVANOVA PLC 325

12.1.4.1  Business overview 325

12.1.4.2  Products offered   326

12.1.4.3  Recent developments           327

12.1.4.3.1                Product launches  327

12.1.4.4  MnM view              327

12.1.4.4.1                Right to win           327

12.1.4.4.2                Strategic choices   327

12.1.4.4.3                Weaknesses & competitive threats     327

12.1.5      NEVRO CORP.    328

12.1.5.1  Business overview 328

12.1.5.2  Products offered   329

12.1.5.3  Recent developments           329

12.1.5.3.1                Product approvals 329

12.1.5.3.2                Deals      330

12.1.5.4  MnM view              330

12.1.5.4.1                Right to win           330

12.1.5.4.2                Strategic choices   330

12.1.5.4.3                Weaknesses & competitive threats     330

12.1.6      NEUROPACE, INC.            331

12.1.6.1  Business overview 331

12.1.6.2  Products offered   332

12.1.7      BIOVENTUS       333

12.1.7.1  Business overview 333

12.1.7.2  Products offered   334

12.1.7.3  Recent developments           335

12.1.7.3.1                Product approvals 335

12.1.8      ELECTROCORE, INC.      336

12.1.8.1  Business overview 336

12.1.8.2  Products offered   337

12.1.8.3  Recent developments           338

12.1.8.3.1                Product launches  338

12.1.8.3.2                Deals      338

12.1.9      HELIUS MEDICAL TECHNOLOGIES, INC.               339

12.1.9.1  Business overview 339

12.1.9.2  Products offered   340

12.1.9.3  Recent developments           341

12.1.9.3.1                Deals      341

12.1.10   NEURONETICS 342

12.1.10.1                 Business overview 342

12.1.10.2                 Products offered   343

12.1.10.3                 Recent developments           344

12.1.10.3.1             Product approvals 344

12.1.10.3.2             Deals      344

12.2         OTHER PLAYERS              345

12.2.1      NEUROSIGMA, INC.         345

12.2.2      SOTERIX MEDICAL INC.                 346

12.2.3      SYNAPSE BIOMEDICAL INC.        347

12.2.4      ALEVA NEUROTHERAPEUTICS  348

12.2.5      THERANICA BIO-ELECTRONICS LTD.     349

12.2.6      GIMER MEDICAL              350

12.2.7      NALU MEDICAL, INC.     351

12.2.8      MICROTRANSPONDER INC.        351

12.2.9      MAGSTIM            352

12.2.10   AMBER THERAPEUTICS                 353

12.2.11   TVNS TECHNOLOGIES GMBH    354

12.2.12   BIOWAVE            355

12.2.13   BIOTRONIK        356

12.2.14   SALUDA MEDICAL PTY LTD.       357

12.2.15   SPR         358

13            APPENDIX           359

13.1         DISCUSSION GUIDE        359

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                363

13.3         CUSTOMIZATION OPTIONS        365

13.4         RELATED REPORTS         365

13.5         AUTHOR DETAILS           366

LIST OF TABLES

TABLE 1                NEUROMODULATION MARKET: INCLUSIONS & EXCLUSIONS      39

TABLE 2                NEUROMODULATION MARKET: KEY DATA FROM PRIMARY SOURCES            46

TABLE 3                MARKET ASSUMPTIONS IN NEUROMODULATION MARKET                 53

TABLE 4                RISK ANALYSIS IN NEUROMODULATION MARKET               54

TABLE 5                POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT

NEUROMODULATION DEVICES                67

TABLE 6                AVERAGE SELLING PRICING TREND OF NEUROMODULATION PRODUCTS,

BY STIMULATION TYPE, 2023–2025 (USD)              70

TABLE 7                AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS,

BY KEY PLAYER, 2023–2025 (USD)              71

TABLE 8                AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS,

BY REGION, 2023–2025 (USD)      71

TABLE 9                ROLE OF KEY PLAYERS IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)    75

TABLE 10              LIST OF KEY PATENTS IN NEUROMODULATION MARKET, 2022–2025          79

TABLE 11              IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)     80

TABLE 12              EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION)     80

TABLE 13              LIST OF KEY CONFERENCES & EVENTS IN NEUROMODULATION MARKET,

JANUARY 2025–DECEMBER 2026 81

TABLE 14              CLASSIFICATION OF MEDICAL DEVICES BY US FDA        84

TABLE 15              NATIONAL MEDICAL PRODUCT ADMINISTRATION (NMPA) MEDICAL

DEVICES CLASSIFICATION          85

TABLE 16              JAPAN: CLASSIFICATION OF MEDICAL DEVICES                 86

TABLE 17              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

TABLE 18              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

TABLE 19              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  88

TABLE 20              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  88

TABLE 21              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  89

TABLE 22              IMPACT OF PORTER’S FIVE FORCES ON NEUROMODULATION MARKET                 90

TABLE 23              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)      91

TABLE 24              KEY BUYING CRITERIA, BY END USER    92

TABLE 25              KEY COMPANIES IMPLEMENTING AI IN NEUROMODULATION MARKET                 94

TABLE 26              US-ADJUSTED RECIPROCAL TARIFF RATES                 95

TABLE 27              NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            99

TABLE 28              INTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)          100

TABLE 29              NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 30              EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 31              ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            101

TABLE 32              LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)          101

TABLE 33              EXTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)          102

TABLE 34              NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            102

TABLE 35              EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            103

TABLE 36              ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            103

TABLE 37              LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)          104

TABLE 38              NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 106

TABLE 39              SPINAL CORD STIMULATION DEVICES OFFERED BY KEY PLAYERS          107

TABLE 40              NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2023–2030 (USD MILLION)                 108

TABLE 41              NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       108

TABLE 42              EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               109

TABLE 43              ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               109

TABLE 44              LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       110

TABLE 45              DEEP BRAIN STIMULATION DEVICES OFFERED BY KEY PLAYERS               111

TABLE 46              NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION,

2023–2030 (USD MILLION)            111

TABLE 47              NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       112

TABLE 48              EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               112

TABLE 49              ASIA PACIFIC: NEUROMODULATION FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)                 113

TABLE 50              LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               113

TABLE 51              SACRAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS          114

TABLE 52              NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)                 114

TABLE 53              NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            114

TABLE 54              EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               115

TABLE 55              ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               115

TABLE 56              LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            116

TABLE 57              VAGUS NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS          116

TABLE 58              NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)                 117

TABLE 59              NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 60              EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               118

TABLE 61              ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               118

TABLE 62              LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            119

TABLE 63              GASTRIC NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS          119

TABLE 64              NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)                 120

TABLE 65              NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            120

TABLE 66              EUROPE: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION,

BY COUNTRY, 2023–2030 (USD MILLION)               121

TABLE 67              ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 121

TABLE 68              LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            122

TABLE 69              TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED

BY KEY PLAYERS               123

TABLE 70              NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION)          123

TABLE 71              NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)                 123

TABLE 72              EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     124

TABLE 73              ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)               124

TABLE 74              LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)                 125

TABLE 75              TRANSCRANIAL MAGNETIC STIMULATION DEVICES OFFERED BY KEY PLAYERS       125

TABLE 76              NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,

BY REGION, 2023–2030 (USD MILLION)   126

TABLE 77              NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     126

TABLE 78              EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       127

TABLE 79              ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            127

TABLE 80              LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     128

TABLE 81              RESPIRATORY ELECTRICAL STIMULATION DEVICES OFFERED BY KEY PLAYERS       128

TABLE 82              NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION,

BY REGION, 2023–2030 (USD MILLION)   129

TABLE 83              NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     129

TABLE 84              EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       130

TABLE 85              ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            130

TABLE 86              LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     131

TABLE 87              OTHER STIMULATION DEVICES OFFERED BY KEY PLAYERS     132

TABLE 88              NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY REGION, 2023–2030 (USD MILLION)                 132

TABLE 89              NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)       132

TABLE 90              EUROPE: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES,

BY COUNTRY, 2023–2030 (USD MILLION)               133

TABLE 91              ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES,

BY COUNTRY, 2023–2030 (USD MILLION)               133

TABLE 92              LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION)       134

TABLE 93              NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            136

TABLE 94              SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION,

2023–2030 (USD MILLION)            137

TABLE 95              NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN,

BY COUNTRY, 2023–2030 (USD MILLION)               137

TABLE 96              EUROPE: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 97              ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN,

BY COUNTRY, 2023–2030 (USD MILLION)               138

TABLE 98              LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 99              SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME,

BY REGION, 2023–2030 (USD MILLION)   139

TABLE 100            NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)            140

TABLE 101            EUROPE: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)       140

TABLE 102            ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)            141

TABLE 103            LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION)            141

TABLE 104            SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION,

2023–2030 (USD MILLION)            142

TABLE 105            NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA,

BY COUNTRY, 2023–2030 (USD MILLION)               142

TABLE 106            EUROPE: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)                 143

TABLE 107            ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION)            143

TABLE 108            LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 109            NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            144

TABLE 110            DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE,

BY REGION, 2023–2030 (USD MILLION)   145

TABLE 111            NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 145

TABLE 112            EUROPE: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 113            ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 114            LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S

DISEASE, BY COUNTRY, 2023–2030 (USD MILLION)           147

TABLE 115            DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION,

2023–2030 (USD MILLION)            147

TABLE 116            NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS,

BY COUNTRY, 2023–2030 (USD MILLION)               148

TABLE 117            EUROPE: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 118            ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)            149

TABLE 119            LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION)            149

TABLE 120            DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION,

2023–2030 (USD MILLION)            150

TABLE 121            NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION,

BY COUNTRY, 2023–2030 (USD MILLION)               150

TABLE 122            EUROPE: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)                 151

TABLE 123            ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)            151

TABLE 124            LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION,

BY COUNTRY, 2023–2030 (USD MILLION)               152

TABLE 125            OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            153

TABLE 126            NORTH AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               153

TABLE 127            EUROPE: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            154

TABLE 128            ASIA PACIFIC: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               154

TABLE 129            LATIN AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 130            NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, BY COUNTRY, 2023–2030 (USD MILLION)                 155

TABLE 131            SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)                 156

TABLE 132            NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)     156

TABLE 133            EUROPE: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE,

BY COUNTRY, 2023–2030 (USD MILLION)               157

TABLE 134            ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 157

TABLE 135            LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 158

TABLE 136            SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2023–2030 (USD MILLION)                 158

TABLE 137            NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION)     159

TABLE 138            EUROPE: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 139            ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 140            LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 141            NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            161

TABLE 142            VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION,

2023–2030 (USD MILLION)            161

TABLE 143            NORTH AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 144            EUROPE: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)            162

TABLE 145            ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION)            163

TABLE 146            LATIN AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 147            OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            164

TABLE 148            NORTH AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               164

TABLE 149            EUROPE: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               165

TABLE 150            ASIA PACIFIC: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               165

TABLE 151            LATIN AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               166

TABLE 152            NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       166

TABLE 153            GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2023–2030 (USD MILLION)                 167

TABLE 154            NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)            167

TABLE 155            EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS,

BY COUNTRY, 2023–2030 (USD MILLION)               168

TABLE 156            ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)            168

TABLE 157            LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION)            169

TABLE 158            GLOBAL NUMBERS OF ADULTS WITH OBESITY (BMI ≥30 KG/M2 ),

BY REGION (BILLION)   169

TABLE 159            GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION,

2023–2030 (USD MILLION)            170

TABLE 160            NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY,

BY COUNTRY, 2023–2030 (USD MILLION)               170

TABLE 161            EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION)                 171

TABLE 162            ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY,

BY COUNTRY, 2023–2030 (USD MILLION)               171

TABLE 163            LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY,

BY COUNTRY, 2023–2030 (USD MILLION)               172

TABLE 164            NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              172

TABLE 165            TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2023–2030 (USD MILLION)       173

TABLE 166            NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION

MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY,

2023–2030 (USD MILLION)            173

TABLE 167            EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)  174

TABLE 168            ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)  174

TABLE 169            LATIN AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION

MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY,

2023–2030 (USD MILLION)            175

TABLE 170            OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 171            NORTH AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     176

TABLE 172            EUROPE: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     177

TABLE 173            ASIA PACIFIC: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     177

TABLE 174            LATIN AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     178

TABLE 175            NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       178

TABLE 176            TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION,

BY REGION, 2023–2030 (USD MILLION)   179

TABLE 177            NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)       179

TABLE 178            EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION,

BY COUNTRY, 2023–2030 (USD MILLION)               180

TABLE 179            ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)       180

TABLE 180            LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION)       181

TABLE 181            TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE,

BY REGION, 2023–2030 (USD MILLION)   181

TABLE 182            NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)       182

TABLE 183            EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE,

BY COUNTRY, 2023–2030 (USD MILLION)               182

TABLE 184            ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)       183

TABLE 185            LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION)       183

TABLE 186            NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION,

BY REGION, 2023–2030 (USD MILLION)   184

TABLE 187            NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     184

TABLE 188            EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)       185

TABLE 189            ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)            185

TABLE 190            LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION)     186

TABLE 191            OTHER NEUROMODULATION APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            186

TABLE 192            NORTH AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               187

TABLE 193            EUROPE: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            187

TABLE 194            ASIA PACIFIC: OTHER NEUROMODULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               188

TABLE 195            LATIN AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               188

TABLE 196            NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)            190

TABLE 197            NUMBER OF HOSPITALS PER CAPITA, BY COUNTRY, 2024 191

TABLE 198            NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION)            191

TABLE 199            NORTH AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)               192

TABLE 200            EUROPE: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)            192

TABLE 201            ASIA PACIFIC: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)     193

TABLE 202            LATIN AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)               193

TABLE 203            NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS,

BY REGION, 2023–2030 (USD MILLION)   194

TABLE 204            NORTH AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)     194

TABLE 205            EUROPE: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 195

TABLE 206            ASIA PACIFIC: NEUROMODULATION FOR CLINICS & PHYSIOTHERAPY CENTERS,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 207            LATIN AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)     196

TABLE 208            NEUROMODULATION MARKET FOR OTHER END USERS, BY REGION,

2023–2030 (USD MILLION)            196

TABLE 209            NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS,

2023–2030 (USD MILLION)            197

TABLE 210            EUROPE: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 211            ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER END USERS,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 212            LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)               198

TABLE 213            NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION)            200

TABLE 214            NORTH AMERICA: KEY MACROINDICATORS                 200

TABLE 215            NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            202

TABLE 216            NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            202

TABLE 217            NORTH AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            203

TABLE 218            NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            203

TABLE 219            NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            204

TABLE 220            NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            204

TABLE 221            NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            204

TABLE 222            NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              205

TABLE 223            NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 205

TABLE 224            NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              205

TABLE 225            NORTH AMERICA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            206

TABLE 226            US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            207

TABLE 227            US: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            207

TABLE 228            US: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       208

TABLE 229            US: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       208

TABLE 230            US: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       208

TABLE 231            US: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       209

TABLE 232            US: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       209

TABLE 233            US: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              209

TABLE 234            US: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            210

TABLE 235            US: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                210

TABLE 236            CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            211

TABLE 237            CANADA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            211

TABLE 238            CANADA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       212

TABLE 239            CANADA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       212

TABLE 240            CANADA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       212

TABLE 241            CANADA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       213

TABLE 242            CANADA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       213

TABLE 243            CANADA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              213

TABLE 244            CANADA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            214

TABLE 245            CANADA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            214

TABLE 246            EUROPE: KEY MACROINDICATORS          215

TABLE 247            EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 248            EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            216

TABLE 249            EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            217

TABLE 250            EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       217

TABLE 251            EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)     218

TABLE 252            EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       218

TABLE 253            EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       218

TABLE 254            EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       219

TABLE 255            EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              219

TABLE 256            EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            219

TABLE 257            EUROPE: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            220

TABLE 258            GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            220

TABLE 259            GERMANY: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            221

TABLE 260            GERMANY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       221

TABLE 261            GERMANY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       222

TABLE 262            GERMANY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       222

TABLE 263            GERMANY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       222

TABLE 264            GERMANY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       223

TABLE 265            GERMANY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              223

TABLE 266            GERMANY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            223

TABLE 267            GERMANY: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            224

TABLE 268            FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            224

TABLE 269            FRANCE: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            225

TABLE 270            FRANCE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       225

TABLE 271            FRANCE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       226

TABLE 272            FRANCE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       226

TABLE 273            FRANCE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       226

TABLE 274            FRANCE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       227

TABLE 275            FRANCE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              227

TABLE 276            FRANCE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            227

TABLE 277            FRANCE: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            228

TABLE 278            UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            228

TABLE 279            UK: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            229

TABLE 280            UK: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       229

TABLE 281            UK: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       230

TABLE 282            UK: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       230

TABLE 283            UK: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       230

TABLE 284            UK: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       231

TABLE 285            UK: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL

NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            231

TABLE 286            UK: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            231

TABLE 287            UK: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                232

TABLE 288            ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            232

TABLE 289            ITALY: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            233

TABLE 290            ITALY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       233

TABLE 291            ITALY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)     234

TABLE 292            ITALY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       234

TABLE 293            ITALY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       234

TABLE 294            ITALY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       235

TABLE 295            ITALY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              235

TABLE 296            ITALY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            235

TABLE 297            ITALY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                236

TABLE 298            SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            236

TABLE 299            SPAIN: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            237

TABLE 300            SPAIN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       237

TABLE 301            SPAIN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       238

TABLE 302            SPAIN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       238

TABLE 303            SPAIN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       238

TABLE 304            SPAIN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       239

TABLE 305            SPAIN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL

NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            239

TABLE 306            SPAIN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            239

TABLE 307            SPAIN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                240

TABLE 308            RUSSIA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            240

TABLE 309            RUSSIA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            241

TABLE 310            RUSSIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       241

TABLE 311            RUSSIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       242

TABLE 312            RUSSIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       242

TABLE 313            RUSSIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       242

TABLE 314            RUSSIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       243

TABLE 315            RUSSIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              243

TABLE 316            RUSSIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            243

TABLE 317            RUSSIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)     244

TABLE 318            REST OF EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            244

TABLE 319            REST OF EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            245

TABLE 320            REST OF EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            245

TABLE 321            REST OF EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            246

TABLE 322            REST OF EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            246

TABLE 323            REST OF EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            246

TABLE 324            REST OF EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              247

TABLE 325            REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 247

TABLE 326            REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              247

TABLE 327            REST OF EUROPE: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            248

TABLE 328            ASIA PACIFIC: KEY MACROINDICATORS                 249

TABLE 329            ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            250

TABLE 330            ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            250

TABLE 331            ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            251

TABLE 332            ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       251

TABLE 333            ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       252

TABLE 334            ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       252

TABLE 335            ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       252

TABLE 336            ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            253

TABLE 337            ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       253

TABLE 338            ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              253

TABLE 339            ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            254

TABLE 340            CHINA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            254

TABLE 341            CHINA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            255

TABLE 342            CHINA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       255

TABLE 343            CHINA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       256

TABLE 344            CHINA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       256

TABLE 345            CHINA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       256

TABLE 346            CHINA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       257

TABLE 347            CHINA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              257

TABLE 348            CHINA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            257

TABLE 349            CHINA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                258

TABLE 350            JAPAN: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            258

TABLE 351            JAPAN: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            259

TABLE 352            JAPAN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       259

TABLE 353            JAPAN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       260

TABLE 354            JAPAN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       260

TABLE 355            JAPAN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       260

TABLE 356            JAPAN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       261

TABLE 357            JAPAN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              261

TABLE 358            JAPAN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            261

TABLE 359            JAPAN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                262

TABLE 360            INDIA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            262

TABLE 361            INDIA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            263

TABLE 362            INDIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       263

TABLE 363            INDIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       264

TABLE 364            INDIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       264

TABLE 365            INDIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       264

TABLE 366            INDIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       265

TABLE 367            INDIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              265

TABLE 368            INDIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            265

TABLE 369            INDIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)                266

TABLE 370            AUSTRALIA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            266

TABLE 371            AUSTRALIA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            267

TABLE 372            AUSTRALIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       267

TABLE 373            AUSTRALIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       268

TABLE 374            AUSTRALIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       268

TABLE 375            AUSTRALIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       268

TABLE 376            AUSTRALIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            269

TABLE 377            AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       269

TABLE 378            AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              269

TABLE 379            AUSTRALIA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            270

TABLE 380            REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            271

TABLE 381            REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)                 271

TABLE 382            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            272

TABLE 383            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            272

TABLE 384            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            272

TABLE 385            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            273

TABLE 386            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              273

TABLE 387            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 273

TABLE 388            REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              274

TABLE 389            REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            274

TABLE 390            LATIN AMERICA: KEY MACROINDICATORS                 275

TABLE 391            LATIN AMERICA: NEUROMODULATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            275

TABLE 392            LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            275

TABLE 393            LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            276

TABLE 394            LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            276

TABLE 395            LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       277

TABLE 396            LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            277

TABLE 397            LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            277

TABLE 398            LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              278

TABLE 399            LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 278

TABLE 400            LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              278

TABLE 401            LATIN AMERICA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            279

TABLE 402            BRAZIL: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            280

TABLE 403            BRAZIL: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            280

TABLE 404            BRAZIL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       281

TABLE 405            BRAZIL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       281

TABLE 406            BRAZIL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       281

TABLE 407            BRAZIL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       282

TABLE 408            BRAZIL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       282

TABLE 409            BRAZIL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              282

TABLE 410            BRAZIL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            283

TABLE 411            BRAZIL: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION)     283

TABLE 412            MEXICO: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            284

TABLE 413            MEXICO: NEUROMODULATION MARKET, BY STIMULATION TYPE,

2023–2030 (USD MILLION)            284

TABLE 414            MEXICO: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       285

TABLE 415            MEXICO: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       285

TABLE 416            MEXICO: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       285

TABLE 417            MEXICO: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,

BY APPLICATION, 2023–2030 (USD MILLION)       286

TABLE 418            MEXICO: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       286

TABLE 419            MEXICO: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              286

TABLE 420            MEXICO: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            287

TABLE 421            MEXICO: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            287

TABLE 422            REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            288

TABLE 423            REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)       288

TABLE 424            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 289

TABLE 425            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 289

TABLE 426            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 289

TABLE 427            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 290

TABLE 428            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 290

TABLE 429            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)       290

TABLE 430            REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            291

TABLE 431            REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            291

TABLE 432            MIDDLE EAST & AFRICA: KEY MACROINDICATORS      292

TABLE 433            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            292

TABLE 434            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION)                 293

TABLE 435            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            293

TABLE 436            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            294

TABLE 437            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            294

TABLE 438            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)            294

TABLE 439            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              295

TABLE 440            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)                 295

TABLE 441            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION)              295

TABLE 442            MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY END USER,

2023–2030 (USD MILLION)            296

TABLE 443            MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NEUROMODULATION MARKET, JANUARY 2022–JULY 2025             297

TABLE 444            NEUROMODULATION MARKET: DEGREE OF COMPETITION 300

TABLE 445            NEUROMODULATION MARKET: REGION FOOTPRINT       303

TABLE 446            NEUROMODULATION MARKET: TECHNOLOGY FOOTPRINT       304

TABLE 447            NEUROMODULATION MARKET: STIMULATION TYPE FOOTPRINT            304

TABLE 448            NEUROMODULATION MARKET: END-USER FOOTPRINT       305

TABLE 449            NEUROMODULATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS             307

TABLE 450            NEUROMODULATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TECHNOLOGY AND REGION      308

TABLE 451            NEUROMODULATION MARKET: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JULY 2025               312

TABLE 452            NEUROMODULATION MARKET: DEALS, JANUARY 2022–JULY 2025               313

TABLE 453            MEDTRONIC: COMPANY OVERVIEW       314

TABLE 454            MEDTRONIC: PRODUCTS OFFERED        316

TABLE 455            MEDTRONIC: PRODUCT APPROVALS, JANUARY 2022–JULY 2025  316

TABLE 456            BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW   318

TABLE 457            BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED    320

TABLE 458            BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS,

JANUARY 2022–JULY 2025               320

TABLE 459            BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–JULY 2025               321

TABLE 460            ABBOTT: COMPANY OVERVIEW                322

TABLE 461            ABBOTT: PRODUCTS OFFERED 323

TABLE 462            ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025   324

TABLE 463            LIVANOVA PLC: COMPANY OVERVIEW  325

TABLE 464            LIVANOVA PLC: PRODUCTS OFFERED   326

TABLE 465            LIVANOVA PLC: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025               327

TABLE 466            NEVRO CORP.: COMPANY OVERVIEW    328

TABLE 467            NEVRO CORP.: PRODUCTS OFFERED     329

TABLE 468            NEVRO CORP.: PRODUCT APPROVALS, JANUARY 2022–JULY 2025               329

TABLE 469            NEVRO CORP.: DEALS, JANUARY 2022–JULY 2025                 330

TABLE 470            NEUROPACE, INC.: COMPANY OVERVIEW                 331

TABLE 471            NEUROPACE, INC.: PRODUCTS OFFERED                 332

TABLE 472            BIOVENTUS: COMPANY OVERVIEW        333

TABLE 473            BIOVENTUS: PRODUCTS OFFERED         334

TABLE 474            BIOVENTUS: PRODUCT APPROVALS, JANUARY 2022–JULY 2025  335

TABLE 475            ELECTROCORE, INC.: COMPANY OVERVIEW                 336

TABLE 476            ELECTROCORE, INC.: PRODUCTS OFFERED                 337

TABLE 477            ELECTROCORE, INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025               338

TABLE 478            ELECTROCORE, INC.: DEALS, JANUARY 2022–JULY 2025             338

TABLE 479            HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW   339

TABLE 480            HELIUS MEDICAL TECHNOLOGIES, INC.: PRODUCTS OFFERED    340

TABLE 481            HELIUS MEDICAL TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JULY 2025               341

TABLE 482            NEURONETICS: COMPANY OVERVIEW  342

TABLE 483            NEURONETICS: PRODUCTS OFFERED   343

TABLE 484            NEURONETICS: PRODUCT APPROVALS, JANUARY 2022–JULY 2025               344

TABLE 485            NEURONETICS: DEALS, JANUARY 2022–JULY 2025        344

TABLE 486            NEUROSIGMA, INC.: COMPANY OVERVIEW                 345

TABLE 487            SOTERIX MEDICAL INC.: COMPANY OVERVIEW                 346

TABLE 488            SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW          347

TABLE 489            ALEVA NEUROTHERAPEUTICS: COMPANY OVERVIEW          348

TABLE 490            THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW   349

TABLE 491            GIMER MEDICAL: COMPANY OVERVIEW                 350

TABLE 492            NALU MEDICAL, INC.: COMPANY OVERVIEW                 351

TABLE 493            MICROTRANSPONDER INC.: COMPANY OVERVIEW          351

TABLE 494            MAGSTIM: COMPANY OVERVIEW             352

TABLE 495            AMBER THERAPEUTICS: COMPANY OVERVIEW                 353

TABLE 496            TVNS TECHNOLOGIES GMBH: COMPANY OVERVIEW          354

TABLE 497            BIOWAVE: COMPANY OVERVIEW             355

TABLE 498            BIOTRONIK: COMPANY OVERVIEW         356

TABLE 499            SALUDA MEDICAL PTY LTD.: COMPANY OVERVIEW          357

TABLE 500            SPR: COMPANY OVERVIEW         358

LIST OF FIGURES

FIGURE 1              NEUROMODULATION MARKET SEGMENTATION & REGIONAL SCOPE    38

FIGURE 2              NEUROMODULATION MARKET: YEARS CONSIDERED    40

FIGURE 3              NEUROMODULATION MARKET: RESEARCH DESIGN                43

FIGURE 4              NEUROMODULATION MARKET: KEY DATA FROM SECONDARY SOURCES    44

FIGURE 5              LIST OF PRIMARY SOURCES IN NEUROMODULATION MARKET                 45

FIGURE 6              NEUROMODULATION MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION     47

FIGURE 7              KEY INSIGHTS FROM PRIMARY EXPERTS IN NEUROMODULATION MARKET                 48

FIGURE 8              REVENUE ESTIMATION OF KEY PLAYERS IN NEUROMODULATION MARKET                 49

FIGURE 9              CAGR PROJECTIONS INNEUROMODULATION MARKET               50

FIGURE 10            NEUROMODULATION MARKET: TOP-DOWN APPROACH         50

FIGURE 11            NEUROMODULATION MARKET: DATA TRIANGULATION             51

FIGURE 12            PARAMETRIC ASSUMPTIONS IN NEUROMODULATION MARKET                 52

FIGURE 13            NEUROMODULATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)      55

FIGURE 14            NEUROMODULATION MARKET, BY STIMULATION TYPE,

2025 VS. 2030 (USD MILLION)      56

FIGURE 15            NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2025 VS. 2030 (USD MILLION)            57

FIGURE 16            NEUROMODULATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      57

FIGURE 17            REGIONAL SNAPSHOT OF NEUROMODULATION MARKET                 58

FIGURE 18            RISE IN GERIATRIC POPULATION AND HIGH DEMAND FOR ADVANCED NEUROMODULATION THERAPIES TO DRIVE MARKET         59

FIGURE 19            CHINA AND HOSPITALS & AMBULATORY SURGERY CENTERS COMMANDED SIGNIFICANT MARKET SHARES IN 2024 60

FIGURE 20            CHINA TO ACCOUNT FOR HIGHEST CAGR DURING STUDY PERIOD               61

FIGURE 21            ASIA PACIFIC TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD       62

FIGURE 22            NEUROMODULATION MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 63

FIGURE 23            TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS

IN NEURMODULATION MARKET              69

FIGURE 24            NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS            72

FIGURE 25            NEUROMODULATION MARKET: SUPPLY CHAIN ANALYSIS            73

FIGURE 26            NEUROMODULATION MARKET: ECOSYSTEM ANALYSIS            75

FIGURE 27            FUNDING AND NUMBER OF DEALS IN NEUROMODULATION MARKET,

2021–2024 (USD MILLION)            76

FIGURE 28            NEUROMODULATION MARKET: TOP 10 PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS APPLIED/GRANTED, 2015–2024  78

FIGURE 29            NEUROMODULATION MARKET: PORTER’S FIVE FORCES ANALYSIS           89

FIGURE 30            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER               91

FIGURE 31            KEY BUYING CRITERIA, BY END USER    92

FIGURE 32            IMPACT OF AI ON NEUROMODULATION MARKET               93

FIGURE 33            NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT       201

FIGURE 34            NUMBER OF PATIENTS WITH ALZHEIMER’S IN US, 2020–2060 (MILLION)               206

FIGURE 35            ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT          249

FIGURE 36            REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET,

2020–2024 (USD MILLION)            299

FIGURE 37            MARKET SHARE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET (2024)   300

FIGURE 38            NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       302

FIGURE 39            NEUROMODULATION MARKET: COMPANY FOOTPRINT       303

FIGURE 40            NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024                306

FIGURE 41            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK

BETA OF KEY VENDORS                310

FIGURE 42            EV/EBITDA OF KEY VENDORS   310

FIGURE 43            NEUROMODULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     311

FIGURE 44            MEDTRONIC: COMPANY SNAPSHOT      315

FIGURE 45            BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT   319

FIGURE 46            ABBOTT: COMPANY SNAPSHOT                323

FIGURE 47            LIVANOVA PLC: COMPANY SNAPSHOT 326

FIGURE 48            NEVRO CORP.: COMPANY SNAPSHOT    329

FIGURE 49            NEUROPACE, INC.: COMPANY SNAPSHOT                 331

FIGURE 50            BIOVENTUS: COMPANY SNAPSHOT        334

FIGURE 51            ELECTROCORE, INC.: COMPANY SNAPSHOT                 337

FIGURE 52            HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY SNAPSHOT   340

FIGURE 53            NEURONETICS: COMPANY SNAPSHOT  343

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• インタラクティブキオスク市場規模、シェア、動向、2030年までの世界予測 2025-11-07
• 精密林業市場規模、シェア、動向、2030年までの世界予測 2025-11-05
• フィールドサービス管理市場規模、シェア、動向、2030年までの世界予測 2025-11-05
• 採血装置市場規模、シェア、動向、2030年までの世界予測 2025-11-04
• 車載半導体市場規模、シェア、動向、2030年までの世界予測 2025-11-04

MarketsandMarkets  出版レポート一覧